{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:59:32Z","timestamp":1794491972718,"version":"4.9.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In cases of an unstable iris-lens diaphragm, intravitreal corticosteroid slow-release implants (CSRI) may accidentally migrate into the anterior chamber, leading to damage to the corneal endothelium. The purpose of this study was to evaluate the efficacy and safety of a suprachoroidal application of these primarily intravitreal implants to address this issue. In this single-center, retrospective proof of principle study, we observed consecutive cases of patients receiving dexamethasone and fluocinolon acetonide implants that were administered into the suprachoroidal space in patients with CME and instability of the iris-lens diaphragm. Treatment responses of the CME on OCT, incidence of secondary intraocular pressure increases, visual acuity and surgery related complications were evaluated. In total, 16 patients were treated and mean follow up was 1.8\u2009\u00b1\u20090.97 months. The procedure was well tolerated with no severe intraoperative or postoperative side effects. Mean central retinal thickness (CRT) decreased significantly from 563.13 to 382.12 (p\u2009=\u20090.002). There was no incidence of steroid induced glaucoma. Mean best corrected visual acuity (BCVA) significantly improved from 1.07 logMAR to 0.65 logMAR (p\u2009=\u20090.01). Suprachoroidal implantation of corticosteroid slow-release implants proves to be a safe and feasible alternative for complex eyes with CME and a disruption of the anterior-posterior segment border. <\/jats:p>","DOI":"10.1038\/s41598-025-05611-y","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T06:31:56Z","timestamp":1750401116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Suprachoroidal implantation of corticosteroid slow release implants for the treatment of cystoid macular edema"],"prefix":"10.1038","volume":"15","author":[{"given":"Ben","family":"Asani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Siedlecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes Benedikt","family":"Schiefelbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schworm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Klaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried G.","family":"Priglinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"issue":"5","key":"5611_CR1","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0002-9394(14)76851-5","volume":"112","author":"AJ Flach","year":"1991","unstructured":"Flach, A. J. et al. Improvement in visual acuity in chronic Aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am. J. Ophthalmol. 112 (5), 514\u2013519 (1991).","journal-title":"Am. J. Ophthalmol."},{"issue":"12","key":"5611_CR2","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/S0161-6420(97)30065-7","volume":"104","author":"AB Thach","year":"1997","unstructured":"Thach, A. B., Dugel, P. U., Flindall, R. J., Sipperley, J. O. & Sneed, S. R. A comparison of retrobulbar versus sub-Tenon\u2019s corticosteroid therapy for cystoid macular edema refractory to topical medications. Ophthalmology 104 (12), 2003\u20132008 (1997).","journal-title":"Ophthalmology"},{"issue":"4","key":"5611_CR3","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.2337\/db07-0982","volume":"57","author":"X Zhang","year":"2008","unstructured":"Zhang, X., Bao, S., Lai, D., Rapkins, R. W. & Gillies, M. C. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 57 (4), 1026\u20131033 (2008).","journal-title":"Diabetes"},{"key":"5611_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00347-012-2737-2","volume":"111","author":"K Schmitz","year":"2014","unstructured":"Schmitz, K. et al. Reliability and safety of intravitreal Ozurdex injections: the ZERO study. Der Ophthalmologe. 111, 44\u201352 (2014).","journal-title":"Der Ophthalmologe"},{"issue":"2","key":"5611_CR5","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1177\/11206721221124688","volume":"33","author":"A Chronopoulos","year":"2023","unstructured":"Chronopoulos, A. et al. Intravitreal Fluocinolone acetonide implant for chronic postoperative cystoid macular edema\u2013two years results. Eur. J. Ophthalmol. 33 (2), 1054\u20131060 (2023).","journal-title":"Eur. J. Ophthalmol."},{"issue":"3","key":"5611_CR6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/ICU.0000000000000365","volume":"28","author":"E Rahimy","year":"2017","unstructured":"Rahimy, E. & Khurana, R. N. Anterior segment migration of dexamethasone implant: risk factors, complications, and management. Curr. Opin. Ophthalmol. 28 (3), 246\u2013251 (2017).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"5611_CR7","unstructured":"Yamane, S. (ed) Transconjunctival intrascleral IOL fixation with double-needle technique. film presented at the ASCRS Symposium on Cataract, IOL and Refractive Surgery New Orleans, Louisiana, USA; (2016)."},{"issue":"2","key":"5611_CR8","first-page":"76","volume":"13","author":"KW Price","year":"2020","unstructured":"Price, K. W., Albini, T. A. & Yeh, S. Suprachoroidal injection of triamcinolone\u2014review of a novel treatment for macular edema caused by noninfectious uveitis. US Ophthalmic Rev. 13 (2), 76 (2020).","journal-title":"US Ophthalmic Rev."},{"issue":"10","key":"5611_CR9","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1097\/IAE.0000000000002279","volume":"39","author":"S Yeh","year":"2019","unstructured":"Yeh, S. et al. Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: a randomized, phase 2 study (DOGWOOD). Retina 39 (10), 1880\u20131888 (2019).","journal-title":"Retina"},{"key":"5611_CR10","unstructured":"Kobin J, Bernarda R, Shannon A, Keller L. Bausch+ lomb and clearside biomedical announce the us commercial launch of xipere\u00ae(triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with uveitis."},{"key":"5611_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40123-020-00232-2","volume":"9","author":"TR Herold","year":"2020","unstructured":"Herold, T. R. et al. Scleral fixation of the Fluocinolone acetonide implant in eyes with severe Iris\u2013Lens diaphragm disruption and recalcitrant CME: the Fluocinolone-Loop-Anchoring technique (FLAT). Ophthalmol. Therapy. 9, 175\u2013179 (2020).","journal-title":"Ophthalmol. Therapy"},{"key":"5611_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s10792-013-9841-4","volume":"34","author":"C Mateo","year":"2014","unstructured":"Mateo, C., Alkabes, M. & Bur\u00e9s-Jelstrup, A. Scleral fixation of dexamethasone intravitreal implant (OZURDEX\u00ae) in a case of angle-supported lens implantation. Int. Ophthalmol. 34, 661\u2013665 (2014).","journal-title":"Int. Ophthalmol."},{"issue":"1","key":"5611_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/IAE.0000000000002196","volume":"39","author":"M Iglicki","year":"2019","unstructured":"Iglicki, M. et al. Dexamethasone implant for diabetic macular edema in Naive compared with refractory eyes: the international retina group real-life 24-month multicenter study. The IRGREL-DEX study. Retina (Philadelphia Pa). 39 (1), 44\u201351 (2019).","journal-title":"Retina (Philadelphia Pa)"},{"issue":"4","key":"5611_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000499540","volume":"62","author":"D Zur","year":"2019","unstructured":"Zur, D., Iglicki, M. & Loewenstein, A. The role of steroids in the management of diabetic macular edema. Ophthalmic Res. 62 (4), 231\u2013236 (2019).","journal-title":"Ophthalmic Res."},{"issue":"11","key":"5611_CR15","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s00417-005-1182-1","volume":"243","author":"IM Gan","year":"2005","unstructured":"Gan, I. M., Ugahary, L. C., van Dissel, J. T. & van Meurs, J. C. Effect of intravitreal dexamethasone on vitreous Vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch. Clin. Exp. Ophthalmol. 243 (11), 1186\u20131189 (2005).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"7","key":"5611_CR16","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1167\/iovs.10-6387","volume":"52","author":"J-E Chang-Lin","year":"2011","unstructured":"Chang-Lin, J-E. et al. Pharmacokinetics of a Sustained-Release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Investig. Ophthalmol. Vis. Sci. 52 (7), 4605\u20134609 (2011).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"1","key":"5611_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/0300060518816884","volume":"47","author":"H Massa","year":"2019","unstructured":"Massa, H. et al. Intravitreal Fluocinolone acetonide implant (ILUVIEN\u00ae) for diabetic macular oedema: a literature review. J. Int. Med. Res. 47 (1), 31\u201343 (2019).","journal-title":"J. Int. Med. Res."},{"key":"5611_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3389\/fncel.2019.00347","volume":"13","author":"AN Salt","year":"2019","unstructured":"Salt, A. N., Hartsock, J. J., Hou, J. & Piu, F. Comparison of the Pharmacokinetic properties of triamcinolone and dexamethasone for local therapy of the inner ear. Front. Cell. Neurosci. 13, 347 (2019).","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"5611_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40942-023-00458-9","volume":"9","author":"EN El Rayes","year":"2023","unstructured":"El Rayes, E. N. & Leila, M. Visual function and retinal morphological changes after single suprachoroidal delivery of Fluocinolone acetonide (Iluvien\u00ae) implant in eyes with chronic diabetic macular edema. Int. J. Retina Vitreous. 9 (1), 20 (2023).","journal-title":"Int. J. Retina Vitreous"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05611-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05611-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05611-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:35:43Z","timestamp":1757190943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05611-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5611"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-05611-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"20 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The following authors declare no Competing Non-Financial Interests but the following Competing Financial interests: Ben Asani receives speaker fees and study support from Novartis AG and a writing Grant from Alcon. Johannes Schiefelbein receives study support from Novartis AG. Tina Herold receives speaker honoraria and study support from Novartis AG and Bayer AG, speaker honoraria from Abbvie, and study support from RocheHolding AG. Jakob Siedlecki receives speaker honoraria and travel reimbursement from Carl Zeiss Meditec AG, Novartis AG, Bayer AG, Pharm-Allergan GmbH, Oculentis OSD Medical GmbH.Consultant: Bayer AG, Novartis AG, Pharm-Allergan GmbH. Travelreimbursement: Oertli AG. Julian Klaas receives speaker fees from Novartis AG. Benedikt Schworm receives Speaker honoraria and travel reimbursement from Novartis AG and Topcon Corporation. Siegfried Priglinger receives speaker and consultant honoraria from and has served on advisory boards for Abbott, Alcon, Geuder, Oculus, Schwind, STAAR, TearLab, Thieme Compliance, Ziemer, Zeiss; has received researchfunding from Abbott, Alcon, Hoya, Oculentis, Oculus, Schwind and Zeiss. Franziska Kruse declares no competing financial or non-financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The data was analyzed anonymously using only the surgical catalogue and OPS-codes to acquire statistical data without any conclusion to patient IDs or name. The ethics committee of the Ludwigs-Maximilians-University Munich issued an issue of no objection and the need for approval was waived (Identifier: 24-0776-KB).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval"}}],"article-number":"20166"}}